Most CNS failures are predictable.

Preclinical data that won't replicate.

Trial designs that can't bridge the species gap.

Phase II signals that were never adequately powered — mistaken for efficacy, then exposed at Phase III scale.

The warning signs are visible earlier than most teams realize, and long before the losses become unavoidable.

Thirty years in translational neuroscience research has taught us exactly where programs break down.

Our assessments are led by a physician-scientist with deep expertise in CNS drug development — integrated with AI-assisted literature synthesis and biomarker analysis.

We identify the gaps between laboratory promise and clinical reality, helping investors make informed decisions and companies strengthen their evidence - before those gaps become costly for both.